Molecular residual disease (MRD) testing is moving into the next phase of precision oncology, extending molecular insight past diagnosis and treatment selection into post-treatment monitoring, surveillance and survivorship. For health systems, the question is not whether to add another test.…
Presented by:
- Rick Baehner, MD, Chief Medical Officer, Precision Oncology Abbott Cancer Diagnostics, Clinical Professor of Pathology,, University of California, San Francisco